Abstract
BackgroundFetuin-A is a hepatic secretory protein that binds to insulin receptors and inhibits insulin resistance (IR) kinase activity as well as IR autophosphorylation in vivo and in vitro.AimThis study aimed to investigate fetuin-A levels in patients with type 2 diabetes mellitus (T2DM) and their relation to microvascular complications.Patients and methodsThis descriptive study was conducted on 160 patients. Group 1 included (n=40) diabetic patients without microvascular complications, group 2 (n=40) included diabetic patients with nephropathy, group 3 (n=40) included diabetic patients with retinopathy, and group 4 represented (n=40) healthy control. Serum fetuin-A and insulin were measured by enzyme-linked immunosorbent assay. Glucose was measured, and homeostasis model assessment for IR (HOMA-IR) was estimated.ResultsFetuin-A levels were significantly higher in all T2DM groups compared with controls. There was a significant positive correlation between fetuin-A, insulin, and HOMA-IR in all studied groups. There was a significant positive correlation between fetuin-A and some of metabolic syndrome criteria in all diabetic patients. There were high significant increases in the mean levels of fetuin-A, insulin, and HOMA-IR in the diabetic patients with nephropathy group than other groups. There was a nonsignificant increase in fetuin-A levels in diabetic patients with retinopathy than the diabetics without microvascular complications.ConclusionFetuin-A may be used as a marker for microvascular complications in T2DM, especially the diabetic nephropathy. Antifetuin drugs may be invented to delay diabetic microvascular complications.
Highlights
Diabetes mellitus (DM) has routinely been described as a metabolic disorder characterized by hyperglycemia that develops because of defects in insulin secretion, insulin action, or both
Fetuin-A may be used as a marker for microvascular complications in Type 2 diabetes mellitus (T2DM), especially the diabetic nephropathy
We evaluated the associations of parameters of microvascular disease in patients with T2DM, DR, and diabetic nephropathy as the degree of protein excretion and renal function with fetuin-A
Summary
Diabetes mellitus (DM) has routinely been described as a metabolic disorder characterized by hyperglycemia that develops because of defects in insulin secretion, insulin action, or both. Diverse biomarkers were studied for identifying of patients with T2DM at microvascular and macrovascular risk. Associations of novel biomarkers such as fetuin-A with metabolic markers or complications do assist to understand their position within the pathophysiology of the vascular disease [5]. Aim This study aimed to investigate fetuin-A levels in patients with type 2 diabetes mellitus (T2DM) and their relation to microvascular complications. Patients and methods This descriptive study was conducted on 160 patients. There was a significant positive correlation between fetuin-A, insulin, and HOMA-IR in all studied groups. There were high significant increases in the mean levels of fetuin-A, insulin, and HOMA-IR in the diabetic patients with nephropathy group than other groups. Antifetuin drugs may be invented to delay diabetic microvascular complications
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
